Koichi Tanaka

Kyoto, Japan

Koichi Tanaka

Nobel Prize

This inventor holds 19 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents, primarily in Mass Spectrometry Methods. Top assignees: Shimadzu Corporation, Omron Corporation, Omron Healthcare Company Ltd.. Active years: 1989-2025. Nobel Prize laureate.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Koichi Tanaka. Retrieved from https://idiyas.com/inventor/koichi-tanaka-3hh3ypn8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 84.2



Average Co-Inventor Count = 2.9

ph-index = 6

Forward Citations = 91(Granted Patents)


Company Filing History:


Years Active: 1989-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Microorganism Identification
Mass Spectrometry
Amino Acid Sequence
Organic Compound Analysis
Health Management
Body Composition Monitor
Glycoprotein Structure
Vibration Control
Printed Circuit Board Inspection
Defective Substrate Repair
Thermal Printer Mechanism
Exercise Assistance
19 patents (USPTO):Explore Patents

Title: Koichi Tanaka: Innovative Methods for Structural Analysis and Protein Cleavage

Introduction:

Koichi Tanaka is a prominent inventor and researcher hailing from Kyoto, Japan. With a total of 13 patents to his name, Tanaka's contributions to the field of structural analysis and protein cleavage have greatly impacted scientific research and analysis techniques. This article delves into Tanaka's latest patents, his notable work experience, and some of his accomplished coworkers.

Structural Analysis of Organic Compounds:

One of Tanaka's latest patents is a method for structural analysis of organic compounds using MALDI (Matrix-Assisted Laser Desorption/Ionization) mass spectrometry. This technique involves three key processes: sample preparation, mass spectrometry analysis, and result interpretation. By precisely preparing the sample and analyzing the generated ions, Tanaka's method allows for the estimation of organic compound structures based on gathered information.

Specific Cleavage of Protein and Peptide Bonds:

Tanaka's innovation is not limited to structural analysis alone. He has also developed a method for the specific cleavage of Cα-C bonds and side chains of proteins and peptides. This patent offers a distinct approach to determining the amino acid sequences of proteins and peptides.

By irradiating proteins or peptides with laser light in the presence of specific hydroxynitrobenzoic acids, Tanaka's method allows for the targeted cleavage of Cα-C bonds and side chains. The resulting fragment ions can then be analyzed through mass spectrometry, enabling the determination of accurate amino acid sequences.

Work Experience and Collaborators:

Tanaka has pursued his research and innovations in esteemed organizations. He has worked for Shimadzu Corporation, a leading company in analytical instrumentation and medical equipment, where he likely made significant contributions to their product development and advancement in the field.

Additionally, Tanaka has collaborated with researchers such as Yuko Fukuyama and Shunsuke Izumi. These collaborations indicate a strong network of scientists working towards further advancements in the field of structural analysis and protein cleavage.

Conclusion:

Koichi Tanaka's patents and research have greatly impacted the scientific community's ability to analyze and understand organic compounds' structures and protein sequences. With the development of innovative methods using MALDI mass spectrometry and specific cleavage techniques, Tanaka has significantly contributed to the field of analytical chemistry. His work continues to inspire and guide researchers worldwide, opening new doors for innovation and understanding within this domain.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…